Bausch + Lomb Corporation research snapshot
BLCO AI stock analysis reads Bausch + Lomb as a global eye health company with a 170-plus-year brand history, diversified product portfolio across contact lenses, pharmaceuticals, and surgical equipment, and improving financial trajectory. The stock has recovered sharply from its April 2025 low of $10.45 to $16.23, supported by two consecutive quarterly earnings beats, positive adjusted EBITDA, and a growing pipeline. However, the company still carries significant debt and reports trailing net losses, making this a high-conviction turnaround thesis rather than a proven compounder.
Current price
$16.23
Market cap
$5.79 billion
AI score
62 / 100
Rating
Turnaround progressing, margin of safety uncertain
Trend status
Recovery from 52-week low of $10.45, now above key moving averages
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Bausch + Lomb monetizes eye health globally through contact lenses, lens care, OTC eye care, prescription pharmaceuticals, and surgical equipment with strong brand recognition. | Medium-high |
| Moat | Brand heritage, regulatory barriers, doctor relationships, contact lens replacement habit, and diversified product lines create a moderate moat. Switching costs are higher in surgical and pharmaceutical segments than in consumer lens care. | Medium |
| Management | CEO Brenton Saunders leads with a focus on operational improvement, debt reduction, and pipeline acceleration. Key-person risk is moderate given the broader management team inherited from the Bausch Health spin-off. | Medium |
| Financial trend | FY2025 revenue was approximately $5.10 billion with a net loss of $360 million, but the last two quarters showed improving profitability with adjusted EPS of $0.08 in Q1 2026. | Medium-high |
| Valuation | At $16.23, BLCO trades at roughly 5.2x trailing revenue and a negative P/E based on TTM results. Enterprise value to revenue is about 6.0x including debt. | Medium |
| Technical trend | The stock has rallied 55% from the April 2025 low of $10.45. The trend is constructive but the move has been sharp, raising the question of how much is already priced in. | Medium |
| Risk level | Key risks are high debt from the Bausch Health separation, negative TTM net income, exposure to China regulatory and competitive dynamics, currency headwinds, and integration of new product launches. | Medium-high |
| AI confidence | The descriptive analysis has medium-high data confidence for reported financials. Turnaround forecasts remain scenario estimates rather than predictions. | Medium-high data confidence |
| Investment certainty | Business improvement has supporting evidence, but debt and loss-making history mean the investment case depends on multi-quarter execution rather than an established moat. | Medium-low |
BLCO AI stock forecast
The BLCO AI stock forecast should be read as scenario math, not a fixed target. Using an estimated normalized forward EPS of $0.50, a July 2026 price near $16.23, and a three-year framework, the tested range spans a bearish area near $5.00, a base area near $12.20, and a bullish area near $24.20. The wide spread reflects the high uncertainty around a turnaround-stage company. Actual outcomes depend on debt reduction pace, margin improvement, product pipeline execution, and market multiple re-rating.
$22.00 to $26.00
More likely if BLCO sustains positive adjusted EPS, delivers on new product launches (Orphia AI platform, glaucoma pipeline), reduces debt ahead of schedule, and the market rewards the turnaround with a mid-20s earnings multiple.
$11.00 to $14.00
More likely if BLCO shows steady but gradual margin improvement, maintains current revenue trajectory, makes modest debt progress, and trades in a 10-16x PE range reflecting the continued losses.
$4.00 to $6.00
More likely if the turnaround stalls, competition from Alcon or J&J intensifies, China revenue weakens, debt refinancing becomes expensive, or the company returns to GAAP net losses.
BLCO AI technical analysis
BLCO AI technical analysis shows a constructive recovery as of the July 12, 2026 data cutoff. The stock traded near $16.23, up significantly from the 52-week low of $10.45 set in April 2025. RSI near 55-60 suggests momentum is positive but not overbought. Volume has been supportive during the rally.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $16.23 | TradingView reported BLCO near $16.23 as of the July 12, 2026 data cutoff. |
| Near support | $14.50 to $15.00 | Prior resistance from May 2026 now flips to support. A pullback to this area would test whether demand holds. |
| Key support | $12.50 to $13.00 | The 50-day moving average has trended higher during the recovery. A move to this zone would be a normal pullback in an uptrend. |
| 52-week low | $10.45 | Set in April 2025. A break below this level would invalidate the recovery thesis and suggest a new downtrend. |
| Near resistance | $17.50 to $18.00 | The stock needs to clear this zone to confirm the uptrend continuation. Prior resistance from late 2025. |
| Upper resistance | $19.50 to $21.00 | The all-time high near $21.95 from June 2023 defines the major upside target for the recovery. |
| All-time high | $21.95 (June 2023) | A move above this level would put BLCO in price-discovery territory for the first time since spin-off. |
| Momentum | RSI near 55-60 | Momentum is positive but not stretched. Room for further upside before reaching typical overbought levels near 70. |
| Volume | Above-average on up days | The recovery rally has been supported by solid volume, suggesting institutional accumulation rather than speculative flow. |
| Volatility | Beta 1.02 | BLCO has roughly market-level volatility. Earnings events and pipeline announcements can create sharp moves. |
| Invalidation | Close below $12.50 | A decisive break below the rising 50-day moving average and the $12.50-$13.00 support zone would weaken the recovery setup. |
BLCO AI trading strategy
The BLCO AI trading strategy below is a framework for research and risk planning, not personal advice. It reflects a turnaround-stage company where fundamental progress matters more than short-term technical signals.
Watch for BLCO to hold above the $14.50-$15.00 support zone and build a base before challenging the $17.50-$18.00 resistance area. Use pullbacks to the 50-day moving average as potential reference points.
Define the invalidation level before entry. A close below $12.50 or the 50-day moving average can be used as a rules-based exit signal.
If BLCO pulls back toward $14-$15 without negative earnings surprises, compare the entry against estimated forward revenue, debt trajectory, and product pipeline milestones.
Avoid buying purely on price momentum. The turnaround thesis depends on earnings delivery, not technical patterns. Size positions knowing the outcome range is wide.
Track Q2 2026 earnings (July 29, 2026), pipeline updates, debt reduction progress, segment-level margins, and management guidance on margins and China revenue.
BLCO can beat reduced estimates and still decline if the market has already priced in improvement. Compare actual results against already-raised expectations.
Investment research summary
Bausch + Lomb sells eye health products across the full care spectrum: contact lenses and lens care, OTC eye drops and supplements, prescription pharmaceuticals, and surgical equipment for cataract and retinal procedures. Customers are consumers, eye doctors, and hospitals who pay for brand trust, regulatory approval, and clinical efficacy.
The moat comes from brand heritage (170-plus years), doctor relationship inertia, regulatory barriers for pharmaceutical products, and the contact lens replacement cycle. The moat is moderate and narrower than Alcon or J&J in most segments.
The thesis fails if the debt burden limits investment and refinancing flexibility, new products fail in clinical trials or don’t gain market share, competition in China intensifies, or margin improvement stalls before reaching profitability.
Brenton Saunders has emphasized operational focus, portfolio optimization, debt reduction, and innovation. The key question is whether management can sustain credibility through the full turnaround cycle, including potential revenue or margin setbacks.
Eye health benefits from aging populations, increasing screen time, growing middle-class demand for vision correction in emerging markets, and steady innovation in contact lenses, dry eye treatments, and cataract surgery technology.
At roughly 5.2x revenue and with a negative TTM P/E, BLCO is priced for a turnaround. The margin of safety is limited until GAAP profitability is demonstrated, but the upside could be significant if the turnaround exceeds expectations.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BLCO price | $16.23 around the July 12, 2026 data cutoff | TradingView BLCO overview | July 12, 2026 |
| Market capitalization | $5.79 billion, calculated from $16.23 x 356.7 million shares | financial_rigor.py market-cap verification | July 12, 2026 |
| Shares outstanding | Approximately 356.7 million shares | TradingView and market-cap back-calculation | July 12, 2026 |
| FY2025 revenue | Approximately $5.10 billion | TradingView fundamentals | July 12, 2026 |
| FY2025 net income | Approximately -$360 million net loss | TradingView fundamentals | July 12, 2026 |
| Q1 2026 adjusted EPS | $0.08 per share, beating $0.05 estimate | Bausch + Lomb Q1 2026 earnings | July 12, 2026 |
| Q1 2026 revenue | $1.24 billion, beating $1.22 billion estimate | Bausch + Lomb Q1 2026 earnings | July 12, 2026 |
| EBITDA | Approximately $724 million, EBITDA margin ~11.9% | TradingView fundamentals | July 12, 2026 |
| Next earnings date | July 29, 2026 (Q2 2026 results) | Bausch + Lomb investor relations | July 12, 2026 |
| Technical levels | 52-week low $10.45, support $14.50, resistance $17.50-$18.00 | TradingView BLCO technical analysis | July 12, 2026 |
This BLCO AI stock analysis page is an informational research tool only. It is not investment advice, financial planning, or a recommendation to buy or sell any security. Forecast scenarios are based on available public data, assumptions, and technical references as of the stated cutoff date and may be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
